You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
一圖看懂兆科眼科(6622.HK)2021年中報業績
格隆匯 08-24 15:24

近日,眼科創新藥物領導者兆科眼科(6622.HK)發佈其2021年半年報業績,其中環孢素A眼凝膠關鍵III期臨牀已達到預設主要研究終點,預計2021年底提交NDA。環孢素A眼凝膠是由兆科眼科自主研發的一種用於治療乾眼症的創新藥物,也是世界上首個每日單次使用的水凝膠。

公司研發支出同比增長224%,達人民幣1.23億元,值得注意的是,截至2021年6月30日,公司的流動資產約為人民幣24.4億元,其中包括現金及現金等價物約為人民幣22.06億元,可謂是“子彈”充足。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account